Author

T. Cihlar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:drug response / drug discovery· 9 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Organism:mouse· 4 Research Focus:benchmarking· 2 Organism:non-human primate· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

J. P. Bilello· 6 shared R. S. Baric· 5 shared T. P. Sheahan· 5 shared D. Babusis· 4 shared J. K. Perry· 4 shared J. Pitts· 4 shared J. Y. Feng· 4 shared V. Du Pont· 4 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

J. P. Bilello

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Discovery and Synthesis of GS-7682, a Novel Prodrug of a 4'-CN-4-Aza-7,9-Dideazaadenosine C-Nucleoside with Broad-Spectrum Potency Against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys.

D. S. Siegel, H. C. Hui, J. Pitts, M. S. Vermillion, K. Ishida, D. Rautiola, M. Keeney, H. Irshad, L. Zhang, K. Chun, G. Chin, B. Goyal, E. Doerffler, H. Yang, M. O. Clarke, , R. L. Mackman

This paper describes the discovery and synthesis of GS-7682, a prodrug with broad antiviral activity against RSV and other viruses, showing efficacy in RSV-infected monkeys.

bioRxiv · Apr 17, 2024 · PreprintBiochemistry

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

D. R. Martinez, F. Moreira, M. R. Zweigart, K. L. Gully, G. De la Cruz, A. Brown, L. E. Adams, N. Catanzaro, B. Yount, T. J. Baric, M. Mallory, H. Conrad, S. R. May, S. Dong, T. D. Scobey, , T. P. Sheahan

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

bioRxiv · Jun 27, 2023 · PreprintMicrobiology

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys

R. L. Mackman, R. Kalla, D. Babusis, J. Pitts, K. T. Barrett, K. Chun, V. Du Pont, L. Rodriguez, J. Moshiri, Y. Xu, M. Lee, G. Lee, B. Bleier, A.-Q. Nguyen, B. M. O'Keefe, , T. Cihlar

bioRxiv · Apr 28, 2023Pharmacology & Toxicology

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants

J. Pitts, J. Li, J. Perry, V. Du Pont, N. Riola, L. Rodriguez, X. Lu, C. Kurhade, X. Xie, G. Camus, S. Manhas, R. Martin, P.-Y. Shi, T. Cihlar, D. P. Porter, , J. P. Bilello

This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.

bioRxiv · Feb 9, 2022Microbiology

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir

L. J. Stevens, A. J. Pruijssers, H. W. Lee, C. J. Gordon, E. P. Tchesnokov, J. Gribble, A. S. George, T. M. Hughes, X. Lu, J. Li, J. K. Perry, D. P. Porter, T. Cihlar, T. P. Sheahan, R. S. Baric, , M. R. Denison

This study identifies distinct mutations in SARS-CoV-2's RdRp that confer remdesivir resistance, showing their biochemical mechanisms and transferability to other coronaviruses.

bioRxiv · Jan 25, 2022 · PreprintMicrobiology

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

A. Schafer, D. R. Martinez, J. J. Won, F. R. Moreira, A. J. Brown, K. L. Gully, R. Kalla, K. Chun, V. Du Pont, D. Babusis, J. Tang, E. Murakami, R. Subramanian, K. T. Barrett, B. J. Bleier, , T. P. Sheahan

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

bioRxiv · Sep 13, 2021 · PreprintMicrobiology

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents

T. N. D. Do, K. Donckers, L. Vangeel, A. K. Chatterjee, P. A. Gallay, M. D. Bobardt, J. P. Bilello, T. Cihlar, S. De Jonghe, J. Neyts, D. Jochmans

This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.

bioRxiv · Mar 25, 2021Microbiology

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

D. Martinez, A. Schaefer, S. R. Leist, D. Li, K. Gully, J. Feng, E. Bunyan, D. Porter, T. Cihlar, S. Montgomery, B. Haynes, R. S. Baric, M. C. Nussenzweig, T. P. Sheahan

This study evaluates combination therapies of remdesivir and monoclonal antibodies for SARS-CoV-2 and its B.1.351 variant in mice, showing improved outcomes with the antibody combination.

bioRxiv · Jan 27, 2021Microbiology

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

P.-Y. Shi, X. Xie, A. E. Muruato, X. Zhang, K. G. Lokugamage, C. R. Fontes-Garfias, J. Zou, J. Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.-T. K. Tseng, S. Makino, V. D. Menachery, J. P. Bilello

This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.

Nature Communications · Oct 15, 2020Peer-reviewedMicrobiology

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology